PBH Prestige Consumer Healthcare Inc

National Survey Shows 84 Percent of Women Admit to Doubting Their Health Choices During Pregnancy

National Survey Shows 84 Percent of Women Admit to Doubting Their Health Choices During Pregnancy

MONISTAT® “Health Below the Bump” Survey Finds Generational Shifts and Uncertainty on How to Manage Health During Pregnancy

TARRYTOWN, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- Can you imagine smoking cigarettes while pregnant? While it would seem controversial today, some women of prior generations engaged in many behaviors that are now widely believed to be harmful for mom, baby or both during pregnancy, according to a new “Health Below the Bump” survey commissioned by MONISTAT®.  The survey found the “rules” of pregnancy have changed dramatically over time, which leaves soon-to-be moms having to decode the latest news and advice to determine how to best manage their health.

The national survey of 2,000 American women who have been or are currently pregnant found that 84 percent doubted the health choices they made during pregnancy, despite many making modifications such as changing what they ate (49 percent), what household cleaning supplies they used (27 percent) and which skin care products they used (22 percent). Doubts likely stemmed from the plethora of information available and advice constantly shifting. In fact, more than one third (36 percent) of respondents feel that there’s an overabundance of information shared during pregnancy.

Yeast Infections and Risks

One health decision that many pregnant women had to face was how to treat a yeast infection, which is as much as 10 times more likely to occur during pregnancy.  Shockingly, the survey revealed that 54 percent of women were not aware that there was a potential health risk when taking the leading prescription pill (fluconazole) to treat yeast infections during pregnancy and nearly half of these women actually took the pill to treat their yeast infections while pregnant.  According to 2019 Canadian study*, women who take any dose of fluconazole during pregnancy are at an increased risk of miscarriage and there may be a link between high levels of fluconazole and increased risk of heart defects in the fetus in the first trimester.

“With the concerns associated with fluconazole during pregnancy, I recommend MONISTAT® 7 Day for vaginal yeast infections in pregnant women,” says Dr. Alyssa Dweck, an OB-GYN, author, women’s health expert and MONISTAT® spokeswoman. “Seven-day topical treatments are the CDC’s only recommended form of yeast infection treatment in pregnant women, and MONISTAT® relieves symptoms four times faster than the prescription oral pill. If you are pregnant, you should consult your healthcare professional prior to using any medication.”

Differing Advice Through the Ages

With so much to worry about during pregnancy, it is not surprising that women are concerned about the choices that they have to make about their health.  More than 25 percent admitted that they received differing advice from other women and 38 percent noted that the information provided by their doctors was significantly different from what their mothers were told when pregnant.  Moreover, the study found that women are also more open to taking advice from strangers, with over 66 percent of women aged 18-24 getting information from online pregnancy forums. 

“With new advancements in medical research each year, health guidelines for pregnancy are often changing and that can lead to confusion for mom, especially when decades of great moms before her likely weren’t privy to the latest guidance,” says, Dr. Dweck. “Of course, there are core guidelines that have stood the test of decades, but as the years progress, there are discernible generational shifts in pregnancy practices given the new information available.”

While doubt and confusion are often present during pregnancy, women should seek comfort in knowing there are knowledgeable experts and trusted products that can aid them in a safe and healthy pregnancy.

For more information on MONISTAT® during pregnancy, visit monistat7.com.

Survey Methodology

This survey was conducted by OnePoll on behalf of MONISTAT® between February 1 and February 7, 2019 among 2,000 American women who have been or are currently pregnant, using an email invitation and an online survey. 

About Prestige Consumer Healthcare, Inc.

The Company markets and distributes brand name over-the-counter healthcare products throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's brands include MONISTAT® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Chloraseptic® sore throat treatments, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, The Doctor's® NightGuard® dental protector, Efferdent® denture care products, Luden's® throat drops, Beano® gas prevention, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at .

*Berard A. Sheehy O, Zhao JP, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019;191:e179-87.

Contact:

Amanda Iodice Acevedo

Coyne PR



973-588-2000

A photo accompanying this announcement is available at

EN
23/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prestige Consumer Healthcare Inc

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Da...

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today rep...

 PRESS RELEASE

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earni...

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.   To participate in the live Internet webcast of the conference call, it can be accessed from the Inv...

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Hal...

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results Revenue of $274.1 million in Q2, ahead of outlookDiluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09Repurchased approximately 1.1 million shares opportunistically in Q2Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and firs...

 PRESS RELEASE

Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Ear...

Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the confere...

 PRESS RELEASE

Prestige Consumer Healthcare to Present at the Barclays Global Consume...

Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 4, 2025 at 12:45 p.m. ET. All interested parties may access a live webcast of this event at under the “Investors” section and the “Events and Presentations” tab, or by using the following link: For those unable to participate during the live webcast, a replay option will be available on the C...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch